Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | AHCY | P23526 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | AMD1 | P17707 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489873 | 1.00 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14929097 | 0.91 | ADORA2A (0.46) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946120 | 0.91 | ADORA2A (0.46) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL18947537 | 0.84 | AHCY (0.50) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL18858889 | 0.82 | AHCY (0.41) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946103 | 0.80 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14928579 | 0.80 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15746179 | 0.80 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15723511 | 0.80 | ADORA2A (0.47) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946122 | 0.77 | ADORA2A (0.48) | ADORA2AADORA2BAHCYDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9089604-B2 | Modified polynucleotides for treating galactosylceramidase protein deficiency | MODERNA THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140221465-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING GALACTOSYLCERAMIDASE PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221465-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING GALACTOSYLCERAMIDASE PROTEIN DEFICIENCY | GBA1, GALC, GALNT1 | ADORA2A 1966/4885ADORA2B 1870/4885AHCY 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.